Key result
Implantable cardioverter-defibrillators offer an effective treatment strategy for preventing sudden death in high-risk patients with hypertrophic cardiomyopathy.
Why the study?
Does the implantable cardioverter-defibrillator prevent sudden death in patients with hypertrophic cardiomyopathy?
Does the implantable cardioverter-defibrillator prevent sudden death in patients with hypertrophic cardiomyopathy?
Implantable cardioverter-defibrillators provide an effective strategy for preventing sudden death in high-risk patients with hypertrophic cardiomyopathy.
Supports ICD consideration in high-risk HCM; leaves open prospective validation of risk stratification.
Sudden unexpected death, often occurring in young, asymptomatic patients, is the most devastating facet of the natural history of hypertrophic cardiomyopathy, and appears to be the consequence of primary ventricular tachyarrhythmias arising in an electrically unstable myocardial substrate characterized by disorganized cellular architecture, ischemia, cell death, and replacement scarring. Although precise identification of all hypertrophic cardiomyopathy patients at high risk for a catastrophic event is a clinical challenge, effective treatment strategies for the prevention of sudden death with the implantable cardioverter-defibrillator are now available.
No takes yet. Share an insight, caveat, or question.
Barry J. Maron (2002) conducted a review in Hypertrophic Cardiomyopathy. Implantable cardioverter-defibrillator was evaluated on Sudden death. Implantable cardioverter-defibrillators offer an effective treatment strategy for preventing sudden death in high-risk patients with hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: